Affymax, (FRA:A5Y) ROE % Adjusted to Book Value : 0.00% (As of Jun. 2014)

View and export this data going back to . Start your Free Trial

What is Affymax, ROE % Adjusted to Book Value?

Affymax,'s ROE % for the quarter that ended in Jun. 2014 was 2,006.05%. Affymax,'s PB Ratio for the quarter that ended in Jun. 2014 was N/A. Affymax,'s ROE % Adjusted to Book Value for the quarter that ended in Jun. 2014 was N/A.

Affymax, ROE % Adjusted to Book Value Historical Data

The historical data trend for Affymax,'s ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax, ROE % Adjusted to Book Value Chart

Affymax, Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-27.80

-2.69

Affymax, Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															Negative Equity	-	-	-	-

Competitive Comparison of Affymax,'s ROE % Adjusted to Book Value

For the Biotechnology subindustry, Affymax,'s ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Affymax,'s ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affymax,'s ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Affymax,'s ROE % Adjusted to Book Value falls into.

Affymax, ROE % Adjusted to Book Value Calculation

Affymax,'s ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2013 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-399.77%	/	N/A
	=	N/A

Affymax,'s ROE % Adjusted to Book Value for the quarter that ended in Jun. 2014 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	2,006.05%	/	N/A
	=	N/A

Affymax, ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Affymax,'s ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Affymax, (FRA:A5Y) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax, Inc. (FRA:A5Y) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020

Website

http://www.affymax.com

Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

Affymax, (FRA:A5Y) Headlines

No Headlines